Megan Browdie

Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Printify, a technology platform headquartered in Latvia that makes it possible for anyone, anywhere, to sell customized products with zero upfront investment, on its merger with Printful, a Latvia-based technology company that helps ecommerce sellers of all sizes use production-on-demand and other fulfillment solutions to turn their ideas into brands and products.

Cooley advised Battery Ventures, a global, technology-focused investment firm, and PageUp Group, a human resources and talent software company that had been majority owned by Battery, on the sale of PageUp to EQT Group.

Cooley advised Veritone, a company building human-centered enterprise artificial intelligence (AI) solutions, on the sale of its media agency, Veritone One, to Insignia Capital Group.